E nvironmental hypoxia is an important cause of pulmonary hypertension worldwide. Reducing alveolar Po 2 causes pulmonary vasoconstriction.
Pamir mountains for a much shorter period, roughly 1000 years. 5 Approximately 14% of Kyrgyz highlanders exhibit ECG signs of pulmonary hypertension while others have normal pulmonary artery pressures. 5 We hypothesized that adult Kyrgyz highlanders who do not experience pulmonary hypertension at altitude may host gene mutations that are protective. We compared the exomes of resident ethnic Kyrgyz highlanders with and without pulmonary hypertension to identify candidate genes that may influence the pulmonary vascular response to hypoxia. An activating mutation was identified in the GUCY1A3 gene, encoding the α subunit of soluble guanylate cyclase (sGC).
Methods

Subjects
In successive visits, standard 12-lead electrocardiography was performed on consenting ethnic Kyrgyz subjects who were permanent residents of villages at 2400 to 3800 m above sea level. Subjects who showed signs of right ventricular hypertrophy and unrelated healthy individuals from the same villages who had a normal cardiovascular system were invited for right heart catheterization. Subjects with obvious clinical or electrocardiography signs of comorbidity (eg, ischemic heart disease or obstructive airway disease) were excluded. Sixty-seven residents (57 men; aged 21 to 75 years) underwent right heart catheterization within 7 days of arrival in Bishkek (760 m above sea level) and provided a DNA sample; 28 individuals were classified as having high-altitude pulmonary hypertension (defined as mean pulmonary artery pressure [mPAP] , ≥25 mm Hg at rest) and 39 as having a normal mPAP ( Figure 1 ; Table I in 
Exome Sequencing
We performed whole exome capture and high-throughput DNA sequencing (see Data Supplement for further details) on 24 unrelated individuals, 12 drawn from the pulmonary hypertensive group and 12 from a group with an mPAP below 25 mm Hg, best matched for sex, age, and altitude of residence ( Figure 1 ; Table 1 ).
A complete methodology is described in the Data Supplement. Exome sequencing libraries were prepared using the Illumina TruSeq Exome Enrichment Kit (62 Mb capture region) and sequenced on the Illumina HiSeq 2000 to generate 100 bp paired-end sequencing reads. Median coverage was ≥40Xfor each sample.
Alignment and Quality Control
Data quality was checked with FastQC (http://www.bioinformatics. bbsrc.ac.uk/projects/fastqc/). Reads were mapped to the GRCh37 reference assembly of the human genome trimming low-quality ends of sequencing reads before alignment.
Single Nucleotide Polymorphism and Indel Calling
Mapped reads were realigned around indels and base call quality scores recalibrated with GATK (Genome Analysis Tool Kit) version 2. Single nucleotide polymorphisms and Indels were called with the GATK Unified Genotyper in multisample mode using only reads with a minimum mapping quality ≥30 and base calls with a minimum quality ≥20. Variant call quality scores were recalibration and variants quality filtered with the GATK Variant Quality Score Recalibrator to select the high-quality variant calls.
Variant Annotation
Variants were annotated using ANNOVAR 6. Minor allele frequency was assessed based on data from the 1000 Genomes Project7 (2012 February release), including a subanalysis of East Asian participants (n=321) and 6500 exomes from National Heart, Lung, and Blood Institute GO Exome Sequencing Project (https://esp.gs.washington. edu/drupal/) data sets. Variants were defined as rare or novel if their minor allele frequency was below 0.5%.
Functional Analysis
Catalytic activity of the GUCY1A3 α 1 -A680T sGC variant was determined using the purified enzyme. Human wild-type (α 1 β 1 ) and the α 1 -A680T (α 1 A680Tβ 1 ) variant of sGC were expressed in Sf9 cells Figure 1 . Distribution of pulmonary artery pressures. The distribution of mean pulmonary artery pressure (mPAP) measurements in a cohort (n=67) of Kyrgyz subjects resident at 2400 to 3800 m above sea level. Two groups (each n=12), classified as normal mPAP or high-altitude pulmonary hypertension (HAPH), were selected for exome sequencing. Arrows indicate subjects with normal mPAP carrying a GUCY1A3 G/A mutation (n=3) that encodes a α1-A680T soluble guanylate cyclase variant. http://circgenetics.ahajournals.org/ Downloaded from using a baculovirus expression system. The enzymes were purified after established procedures. 6 The dependence of catalytic activity of wild-type and α 1 -A680T variant of sGC on nitric oxide (NO) was determined using the NO donor, DEA/NO. Purified sGC was incubated with DEA/NO for 1 minute before initiation of the reactions with GTP/MgCl 2 . The reactions were quenched after 3 minutes, and cyclic guanosine monophosphate (cGMP) was quantified by enzyme-linked immunosorbent assay (Enzo Life Sciences).
The functional activity of the α 1 -A680T sGC variant was also evaluated in 2 cell lines; a cGMP reporter cell line, consisting of Chinese hamster ovary cells that stably express the cGMP-dependent cation channel cyclic nucleotide gated channel 2, that permits real-time cGMP detection, and HEK293 cells. Chinese hamster ovary cells were cotransfected with wild-type rat sGC-α 1 and sGC-β 1 subunit cDNA or a GUCY1A3 mutant encoding the specific A680T protein variant identified in Kyrgyz subjects. *Substitution dbSNP rs199708920 A->C (Thr->Pro) exists at position. Function: nonsynonymous single nucleotide variant unless indicated. Genes are named after the nomenclature of Human Gene Organisation Gene Nomenclature Committee. dbSNP indicates single nucleotide polymorphism database; fs frame shift; HAPH, highaltitude pulmonary hypertension; mPAP, mean pulmonary artery pressure; and NHLBI, National Heart, Lung, and Blood Institute. 
Statistical Analysis
Data are presented as the mean±SE of the mean or half-maximal effective concentration (EC 50 ) and 95% confidence interval (CI). Normality was assessed using the Kolmogorov-Smirnov test and comparisons between 2 groups were performed using the 2-tailed Student t test or χ 2 test. Dose-response curves were analyzed by nonlinear regression (Hill Slope) analysis with EC 50 calculated for subsequent comparison between experimental conditions. To compare conditions at different concentrations of stimuli, activity data were also analyzed by repeated measures ANOVA, with Bonferroni post-tests. Other data were assessed by 2-way ANOVA, as appropriate, with Bonferroni post-tests. Statistical significance was accepted at P<0.05. Analyses and curve fitting were performed with GraphPad Prism 5.0 (GraphPad Software, San Diego, CA).
Results
Exome Sequencing
A total of 140 789 exomic variants were identified and 26 116 (18.5%) were classified as novel or rare with 22 232 of these not previously recorded in single nucleotide polymorphism database (Table II in the Data Supplement). To prioritize those with possible large effects, we selected rare and novel coding protein sequence changing variants found exclusively either in subjects from the group with high-altitude pulmonary hypertension or subjects from the group with normal mPAP, with ≥3 individuals from that group exhibiting the variant. This arbitrary cutoff represented ≥25% of the sample and provided a reasonable number of variants to pursue as candidates. Thirty-three variants fulfilled these criteria (Table 2 ) and the group with a normal mPAP hosted variants in 2 genes, GUCY1A3 (guanylate cyclase 1, soluble, α) and PTGS1 (prostaglandin-endoperoxide synthase 1), associated with signaling pathways relevant to the pharmacological management of pulmonary hypertension. 7 We selected the GUCY1A3 variant, encoding an α 1 -A680T sGC variant, for functional investigation as (1) it resides in the highly (2) it is the only gene that cross-referenced with a previously published a priori list of functional candidates associated with high-altitude adaptation, 8 and (3) it has been shown experimentally to be expressed in lung vasculature at both mRNA and protein level (Table III in the Data Supplement). Three subjects with a normal mPAP who came from different clans and were unrelated (see Data Supplement for test of relatedness) carried the GUCY1A3 α 1 -A680T sGC variant. The mutation was validated by polymerase chain reaction amplification of the variant-containing exon and Sanger sequencing. The mutation was not identified in the remainder of the study cohort. The distribution of other novel variants in the 3 subjects with GUCY1A3 α 1 -A680T sGC is given in the Data Supplement (Table IV in the Data Supplement).
Functional Analysis
Activity of the purified wild-type and α 1 -A680T variant of sGC in the basal and fully NO-activated state were similar ( Figure 2 ). However, the EC 50 of DEA/NO was lower for the α 1 -A680T sGC variant (P<0.0001). The α 1 -A680T EC 50 was 260 nmol/L (95% CI, 230-290 nmol/L), compared with the sGC wild-type EC 50 of 490 nmol/L (95% CI, 440-520 nmol/L). Taking into account the rate of NO formation from DEA/NO at pH 7.4 and 25°C, the EC 50 for NO can be estimated as 100 and 50 nmol/L for wild-type and α 1 -A680T variant, respectively. Although the increased NO sensitivity of the α 1 -A680T sGC is subtle, the effect occurs over a physiologically relevant NO concentration range.
Further functional analysis was conducted in 2 cell lines. The Chinese hamster ovary cGMP reporter assay has been used as a high-throughput-screening strategy for the identification of residues crucially involved in the binding of the heme moiety at sGC and activation of sGC [9] [10] [11] and dimerization of sGC. 12 Chinese hamster ovary cells expressing the α 1 -A680T sGC variant possessed greater (P<0.01) . Phylogenetic analysis of soluble guanylate cyclase (sGC) α 1 homolsogs. Phylogenetic tree of human sGC α1 subunit homologs showing sequences where Ala680 is conserved (red) or mutated to Ala680Thr mutation (green). The homologs of human sGC α1 were collected from UNIREF90 using search algorithm Context-Specific Iterated-Basic Local Alignment Search Tool (CSI-BAST). A Bayesian consensus tree was derived from amino acid alignments constructed using multiple alignment using fast Fourier Transform. The inset shows sequences that belong in the branch containing mammalian, bird, and reptile sGC α1 subunits. by guest on July 31, 2017 http://circgenetics.ahajournals.org/ Downloaded from basal cGMP production compared with cells expressing wild-type sGC ( Figure 3A ). An increase in cGMP production (P<0.001) in response to NO donors was observed in both the cells expressing the wild-type and cells expressing the α 1 -A680T variant of sGC, but cells expressing the α1-A608T variant showed >2-fold greater cGMP production compared with the wild-type control ( Figure 3B-D) . BAY 41-2272 represents a class of compounds that stimulate sGC directly in an NO-independent manner, increasing enzyme activity and synergizing with the NO donor DEA/ NO over a wide range of concentrations. 13, 14 There was a concentration-dependent increase in cGMP production in response to BAY 41-2272 alone and this was significantly Figure 4) .
Activity of the α 1 -A608T variant was investigated further in a second cell assay. Enzyme activity was determined in cytosolic fractions after transient expression of human sGC subunits in HEK293 cells. 15 Under conditions of equivalent expression as demonstrated by Western blot analysis, activity of the α 1 -A608T variant was significantly higher than the wildtype α 1 under basal conditions, in the presence of DEA/NO and the combined presence of DEA/NO and BAY 41-8543, an sGC stimulator related to BAY 41-2272 16 (P<0.05, n=8; Figure 5 ).
Discussion
Genetic studies of high-altitude populations to date have focused on comparing the genomes of highlanders with those from lowlanders. This is the first study comparing the exomes of a resident highland population carefully phenotyped by direct pulmonary artery pressure measurements. Thirty-three novel or rare nonsynonymous variants were identified that were exclusive to either subjects with high-altitude pulmonary hypertension or subjects with normal pulmonary artery pressure, with ≥3 individuals exhibiting the variant. A rare α 1 -A680T sGC variant found in 3 unrelated highlanders with a normal mPAP alters the amino acid sequence in the highly conserved C-terminal catalytic domain and is biologically relevant to pulmonary vascular homeostasis. Isolated enzyme and 2 cell-based assays demonstrate that the variant is associated with increased sGC activity, which would act to confer protection against pulmonary hypertension in a hypoxic environment. The NO-sGC-cGMP signaling pathway is an important regulator of pulmonary vascular homeostasis. Pharmacological or genetic inhibition of NO synthase, particularly the endothelial isoform, increases hypoxic pulmonary vasoconstriction in rodents. 17, 18 Both inhaling NO 19 and inhibition of cGMP hydrolysis using the phosphodiesterase type 5 inhibitor, sildenafil, 20 reduce acute hypoxia-induced pulmonary hypertension and chronic sildenafil use reduces established pulmonary hypertension in resident highlanders. 21 The most common isoform of sGC is active as a heterodimer, composed of an α1 subunit and a heme-containing β1 subunit, and expressed in the smooth muscle layer of the pulmonary vascular wall. [22] [23] [24] The binding of NO to the heme in sGC results in activation and synthesis of cGMP, which mediates vasorelaxation and inhibits vascular cell proliferation. Reduction in the bioavailability of NO or insensitivity of sGC to NO decreases cGMP production and promotes pulmonary hypertension. Deficiency of α 1 -sGC in mice does not affect the acute vasoconstrictor response to hypoxia but selectively inhibits the pulmonary vasodilator response to NO and increases pulmonary vascular remodeling in chronic hypoxia. 25 Conversely, pharmacological activation of sGC attenuates hypoxia-induced pulmonary vascular remodeling and pulmonary hypertension in rodent models. 23, 26 Consequently, the α 1 -A680T sGC polymorphism, which results in higher activity of the enzyme in intact reporter cells and cytosolic fractions and increased sensitivity of the isolated enzyme to NO, would be expected to protect against pulmonary vascular remodeling and pulmonary hypertension during exposure to chronic hypoxia at high-altitude.
Interestingly, the purified wild-type and α 1 -A680T variant of sGC have similar basal and NO-activated activity (NO-activated activities are within the error of measurement) while the cell-based activity assays showed a significant increase in cGMP production in cells expressing the α 1 -A680T variant, in both in the basal and NO-activated state ( Figure 3A-D) . In addition, there was a small increase in cGMP levels in response to the sGC stimulator (BAY 41-2272; Figure 4 ) in cells expressing α 1 -A680T variant compared with wild-type. The studies in HEK293 cells ( Figure 5 ) suggest that the difference observed between cell-based assays and purified enzyme is not a result of changes in the expression of the α 1 -A680T variant, but more likely attributable to additional factors such as differences in subcellular localization or protein-protein interactions. In fact, the apparent difference in effects as determined by purified versus cell-based assays reveals an interesting role for broader cellular regulation in sensitizing and amplifying sGC activity. Relevant to this, the α 1 -A680T mutation is found on the C terminus, a region implicated by Koesling et al 27 in subcellular targeting of the α2β1 isoform of sGC. This region of the α-subunit C-sequence is thought to be important for interactions with scaffolding proteins and membrane association. In addition, heat shock protein 90 and CCTη are also thought to be interacting with sGC in vivo. 28, 29 A recent study demonstrated that loss of function mutations in α 1 -sGC and CCTη are associated with myocardial infarction. 30 We hypothesize that the physiological effects of the α 1 -A680T sGC variant are mediated by the combined effect of a subtle increase in NO sensitivity as well as changes in protein-protein interactions or localization in cells.
To take a more detailed analysis of the terminal region of the α 1 -subunit sequence, we carried out a phylogenetic analysis of sGC α 1 homologs ( Figure 6 ). This analysis revealed that Ala680 is only conserved in α 1 sGC of mammals and birds. An alignment of mammalian α 1 sGC sequences demonstrated that the last 12 residues in the C terminus (Homo sapiens α1 679 to 690), including Ala680, are highly conserved (Figure 7 ). However, a sequence alignment of sGC α subunits, including lower organisms showed that while majority of the catalytic domain is highly conserved, the last 32 residues (H sapiens α1 659 to 690) are variable when comparing mammals, fish, and invertebrate sGC ( Figure I in the Data Supplement). Interestingly, the last 12 residues in reptile sGC α 1 are identical to mammalian sGC with a few exceptions including an Ala680Thr mutation ( Figure I in the Data Supplement). Taken together, these results indicate that Ala680 is not directly involved in catalysis, but rather plays a regulatory role in mammalian sGC signaling, as suggested above.
Studies in mice show that α 1 -sGC is required for the pulmonary but not the systemic vasodilator response to NO. 25 A recent genome-wide association study identified many loci associated with systemic hypertension, including 1 containing GUCY1A3 and GUCY1B3 genes, encoding α 1 and β 1 subunits of sGC, 31 but the polymorphism is distinct from the variant found in our Kyrgyz cohort. Some strains of male mice deficient in α 1 -sGC are prone to systemic hypertension and the renin-angiotensin-aldosterone system may be a blood pressure modifying mechanism in this setting. 32 The observation that the α 1 -A680T sGC variant increases sensitivity to NO is important as oxygen availability is a major determinant of NO production. 33 Part of the adaptive response of Tibetans to altitude may be related to their apparent ability to better preserve NO biosynthesis at altitude than less well-adapted comparators. The levels of NO in exhaled breath in Tibetans at 4200 m are more than twice those recorded in volunteers at low altitude. 34 Tibetans also have >10-fold higher circulating concentrations of bioactive NO products, including plasma and red blood cell nitrate and nitroso proteins and plasma nitrite, than US residents at low altitude (206 m). 35 These data are thought to explain higher pulmonary blood flow in Tibetans. 36 The biochemical explanation for the preservation of pulmonary NO biosynthesis in Tibetans is, however, unclear. Moreover, it may not be a universal mechanism of adaptation. Studies of the Aymara of Bolivia (who reside at 3900 m) have recorded exhaled NO levels only 25% higher than lowlanders and, unlike Tibetans, does not increase further on inspiration of oxygen. 34 Genetic studies of Tibetans to date have revealed higher frequencies of polymorphisms in genes involved in oxygen homeostasis compared with lowlanders. 8, [37] [38] [39] [40] [41] Among these are the genes for the oxygen sensor EGLN1 (also known as prolyl hydroxylase-2) and the transcription factor EPAS1 (also known as hypoxia inducible factor-2 α). The most common EGLN1 and EPAS1 variants among Tibetans were associated with lower hemoglobin concentration. Recently, evidence for selective pressure on a mutation in the µ-opioid receptor-encoding gene (OPRM1, 2.54_10_9), which has been implicated in the stimulation of respiration, has been presented with the suggestion that it may assist adaptation to altitude. 42 Adaptation to life at high altitude clearly involves a complex interplay of many genes. The key variants conferring benefit at high altitude likely differ between populations. Variants found in EGLN1 and EPAS1 have not been found in Andean highlanders, and were not seen in our Kyrgyz cohort (data not shown).
There are limitations to this study. First, cardiac catheterization was performed at 760 m, within a week of arrival in Bishkek, rather than at altitude. But hypoxia-induced pulmonary hypertension does not abate immediately on descent to low altitude. Although any vasoconstrictor component may resolve, vascular remodeling maintains a high pulmonary vascular resistance in the short term. Furthermore, follow-up measurements by echocardiography in the 3 subjects with the α 1 -A680T sGC polymorphism at their place of residence showed that their pulmonary pressures remained in the normal range (systolic pulmonary artery pressures of 30, 32, and 35 mm Hg, respectively) at altitude, compared with subjects with pulmonary hypertension returning home (mean±SD, 67±19 mm Hg).
Second, our study cohort is small and the α 1 -A680T sGC variant was detected in only 3 individuals, giving a prevalence of 3 of 39 (8%) in the healthy controls and 0 of 28 in those with high-altitude pulmonary hypertension. Although this is a higher prevalence than in the general (0.0005%; Table 2) or Asian (0.0017%; Table 2 ) population, the variant needs further evaluation in a larger population in which pulmonary artery pressure measurements are available.
Third, the effects of the α 1 -A680T sGC variant on sGC activity has not been examined in cells from the 3 individuals expressing this gene. This is technically challenging as the cells of interest are pulmonary vascular smooth muscle cells, but another accessible cell type (eg, skin fibroblasts, platelets, or blood outgrowth endothelial cells) might act as a useful surrogate.
Fourth, other variants were identified in this research that have not been investigated further in functional studies. To do so with same thoroughness used for the α 1 -A680T sGC variant is beyond the scope of this report. Consideration should be given to including these in future studies of the genetic architecture of populations adapted to high-altitude living to help prioritize selection for further functional evaluation.
Finally, it is not currently possible to conclude whether the variants detected in this study were de novo or inherited as by by guest on July 31, 2017 http://circgenetics.ahajournals.org/ Downloaded from design the subjects in this study were not related and further samples from parents or siblings were not collected.
Understanding genetic adaptation to high-altitude life can provide an important insight into pathophysiology and support novel drug targets in humans. The finding of a rare gainof-function mutation in GUCY1A3 in Kyrgyz highlanders (long-term resident at 2400 to 3800 m) who do not develop pulmonary hypertension at altitude provides validation in humans for the concept that stimulation of sGC is a potential pharmacological strategy for reducing pulmonary artery pressure in humans living at high-altitude.
In the article by Wilkins et al, "α1-A680T Variant in GUCY1A3 as a Candidate Conferring Protection From Pulmonary Hypertension Among Kyrgyz Highlanders," which appeared in the December 2014 issue of the journal (Circulation: Cardiovascular Genetics. 2014;7:920-929), there was an error with an author name. "Nur Basek Surmuli" should have been "Nur Basak Surmeli".
The correction has been made online. The publisher regrets the error. 
SUPPLEMENTAL MATERIAL
Kyrgyz subjects
Sixty seven residents (aged 21-75 years) underwent right heart catheterization and pulmonary hypertension (defined as mean pulmonary artery pressure (mPAP) ≥25 mmHg at rest) was confirmed in 28 individuals (Supplementary Table 1 ). 
Supplementary
Alignment and quality control
Data quality was checked for a number of quality matrices using FastQC (http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/). De-multiplexed FASTQ files were aligned to the human genome build hg19 using BWA 1 . We used base quality trimming cutoff of 20 with disabling Smith-Waterman for the unmapped mate, which avoids mapping reads with more than 14 mismatches to the reference genome. The rest of the alignment parameters were used as default. Aligned BAM files were processed using GATK (Genome Analysis Toolkit) 2 , Picard (http://picard.sourceforge.net) and SAMtools 3 to obtain high quality analysis ready bam files. Initially read pairs with same start position were marked as PCR duplicates using Picard tools Mark Duplicates functionality. Duplicate marked bam files were realigned at insertion-deletion (Indels) sites to correct the mismatched bases on the edges of Indels which often falsely counted as an evidence for SNPs. Unusual mate-pair distances due to realignment were fixed using Picard tools. In the final step, the quality scores for each base were recalibrated to produce the analysis ready bam files. Quality score recalibration corrects the base qualities score values, which are often incorrectly scaled by the base-callers during sequencing 4 . Wherever possible, the pre-processing and quality control steps were performed in multi-sample modes on control and HAPH samples.
SNP and Indel calling
SNPs and Indels were called using GATK multisample mode with minimum mapping quality ≥30 and base quality ≥20. For SNPs, we used GATK's variant quality score recalibration (VQSR) to select the high quality variants. VQSR builds an adaptive error model using known SNPs from dbSNP, 1000 genome and HapMap3.3 datasets, the adaptive error model was then applied to estimate the probability for each variant to separate true genetic variant from alignment or sequencing errors. We selected variants with true positive sensitivity >90% and Ti/Tv ration 2.62, the Ti/Tv ratio being close to the expected ratio of 3.0 for exome datasets 4 . A slightly lower than expected Ti/Tv in our dataset can be explained by inclusion of ~50% UTR regions in the Illumina TruSeq Exome Enrichment Kit as compared to other Exome kits 5 . Indels were filtered out using the GATK VariantFiltrationWalker with following parameters QD<2, ReadPosRankSum < -20, InbreedingCoeff < -0.8 and FS >200.
Variant annotation
The variants were annotated using ANNOVAR software 6 . The 1000 Genomes Project 
Relatedness
The Kyrgyz society is exogamic and study subjects were considered to be unrelated for at least 4-5 generations. Moreover, identity by descent (IBD) analysis was conducted among all pairs of individuals, based on >2000 independent common variants from the exome data set, and indicated that there was no relatedness down to third-degree relatives. 
Supplementary
cGMP reporter cells
To evaluate the functional activity of the wild type and α 1 -A680T sGC variant we used transfected Chinese hamster ovarian (CHO) cells as cGMP reporter cells 9 . Briefly, the CHO cells were stably transfected with the cGMP-gated Ca 2+ -channel CNG2 and aequorin, which translates increasing levels of intracellular Ca 2+ into bioluminescence. In addition, the cells were transiently cotransfected with WT-sGC (α 1 and β 1 subunits of rat sGC) or α1A680T-sGC and β 1 -sGC. The α 1 -A680T sGC polymorphism resides in the highly conserved C-terminal catalytic domain (amino acids 467-690) of the α 1 -sGC subunit, with 95% homology between the rat and human sequences 10, 11 .
To determine the sGC activation profile, cells were incubated for 10 min at room temperature with increasing concentrations of nitric oxide (NO) donors (DEA/NO, SNP, SIN-1), sGC stimulator BAY 41-2272, or sGC activator BAY 58-2667, both in the absence or presence of 1 nM DEA/NO or 10 µM ODQ. 3-Isobutyl-1-methylxanthin (66.7 nM) was added to all buffers to prevent cGMP degradation by endogenous phosphodiesterases. The bioluminescence was initiated by addition of 10 mM CaCl 2 and correlates directly with the intracellular cGMP content 9 .
Expression of human sGC variants in HEK293 cells
The human α 1 cDNA and the human β 1 cDNA were both transferred BamHI / XhoI from pFASTBAC into the pcDNA3.1/V5/HisTOPO expression vector as described previously 13 .
HEK293 cells were cultivated in Dulbecco's Modified Eagle Medium-High Glucose with 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C with 5% CO 2 . Lipofectamine LTX was used for transfection. 48 h after transfection HEK293 cells were harvested using a disposable cell scraper and centrifuged at 1500 x g for 10 min at 4 °C. All the following steps were performed at 4 °C or on ice. The cell pellet was resuspended in 4 ml of homogenization buffer containing 50 mm triethylammonium/HCl, pH 7.6, 0.2 µm benzamidin, 1 mm EDTA, Cytosolic fractions were obtained by a second centrifugation step for 30 min at 40,000 × g.
Enyzme activity determination was done as recently described 14 . For immunoblotting, protein fractions were subjected to 10% SDS-PAGE and then transferred electrophoretically to a nitrocellulose membrane. The membrane was reversibly stained with Ponceau S, and unspecific binding sites were saturated by immersing the membrane for 1 h in TBST buffer (10 mM Tris/HCl, pH 8.0, 150 mM NaCl, 0.05% Tween 20) containing 5% nonfat dry milk.
The membranes were incubated for 1 h in TBST buffer containing antibodies directed against the β 1 and α 1 sGC subunits.
